Endothelial function of the human renal vasculature;Endothelfunktion im nierenstromgebiet des menschen

Deutsche Medizinische Wochenschrift

Volumn 128, Issue 3, 2003, Pages 92-96

  Delles, C ^a   Schmieder, Roland E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ARGININE; CALCIUM ANTAGONIST; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIDAPRIL; LOSARTAN; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; NIFEDIPINE; NITRIC OXIDE SYNTHASE INHIBITOR; PRAVASTATIN; RAMIPRIL; VALSARTAN;

BLOOD VESSEL TONE; CLINICAL ARTICLE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY BLOOD FLOW; REVIEW; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

ARGININE; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; KIDNEY; KIDNEY FAILURE; NITRIC OXIDE SYNTHASE; REGIONAL BLOOD FLOW; VASCULAR RESISTANCE; VASODILATION;

EID: 0037449688     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-36659     Document Type: Review

References (50)

1. Avontuur JAM, Buijk SLCE, Bruining HA. Distribution and metabolism of NG-nitro-L-arginine methyl ester in patients with septic shock. Eur J Clin Pharmacol 1998; 54:627-631
2. Bachmann S, Bosse HM, Mundel P. Topography of nitric oxide synthesis by localizing constitutive NO synthases in mammalian kidneys. Am J Physiol 1995; 268:F885-F998
3. Barba G, Vallance PJ, Strazzullo P et al. Effects of sodium intake on the the pressor and renal responses to nitric oxide synthesis inhibition in normotensive individuals with different sodium sensitivity. J Hypertens 2000; 18:615-621
4. Barri YM, Wilcox CS. Salt intake determines the renal response to L-arginine infusion in human subjects. Kidney Int 1998; 53:1299-1304
5. Bayerle-Eder M, Fuchsjäger-Mayerl G, Sieder A et al. Effect of pravastatin on responsiveness to N-monomethyl-L-arginine in patients with hypercholesterolaemia. Atherosclerosis 2002; 160:177-184
6. Bech JN, Nielsen CB, Pedersen EB. Effects of systemic NO synthesis inhibition on RPF, GFR, UNa, and vasoactive hormones in healthy humans. Am J Physiol 1996; 270:F845-F851
7. Bech JN, Svedsen KB, Nielsen CB, Pedersen BP. The systemic renal response to NO inhibition is not modified by angiotensin-II-receptor blockade in healthy humans. Nephrol Dial Transplant 1999; 14:641-647
8. Berger ED, Bader BD, Rüb N et al. Changes in renal and systemic hemodynamics after NO-synthase inhibition in males with family history of hypertension. Kidney Blood Press Res 2002; 25:42-49
9. Böger RH, Bode-Böger SM, Szuba A et al. Asymmetrical dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98:1842-1847
10. Bournier M, Pechère-Bertschi A, Nussberger J et al. Studies of the renal effects of angiotensin II receptor blockade: The confounding factor ofacute water loading on the action of vasoactive systems. Am J Kidney Dis 1995; 26:105-115
11. Broere A, van den Meiracker AH, Boomsma F et al. Human renal and systemic hemodynamic, natriuretic, and neurohumoral responses to different doses of L-NAME. Am J Physiol 1998; 275:F870-F877
12. Cole RB, Giangiacomo J, Ingelfinger JR et al. Measurement of renal function without urine collection. A criticai evaluation of the constant-infusion-technique for determination of inulin and para-aminohippurate. N Engl J Med 1972; 287:1109-1114
13. Delles C, Jacobi J, John S, Fleischmann I, Schmieder RE. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. Kidney Int 2002; 61:1462-1468
14. Delles C, Jacobi J, Schlaich MP, John S, Schmieder RE. Assessment of endothelial function of the renal vasculature in human subjects. Am J Hypertens 2002; 15:3-9
15. Delles C, Klingbeil AU, Schneider MP, Handrock R, Schmieder RE. Disparate effects of valsartan vs. amlodipine on renal hemodynamics and endothelial function: a double blind, randomized, controlled trial (Abstrakt). Dtsch Med Wochenschr 2001; 126 (Suppl 3); S158
16. Dijkhorst-Oei LT, Beutler JJ, Stroes ES et al. Divergent effects of ACE-inhibition and calcium channel blockade on NO-activity in systemic and renal circulation in essential hypertension. Cardiovasc Res 1998; 40:402-409
17. Egashira K, Suzuki S, Hirooka Y et al. Impaired endothelium-dependent vasodilation in large epicardial and resistance coronary arteries in patients with essential hypertension: different responses to acetylcholine and substance P. Hypertension 1995; 25:201-206
18. Fleischmann E, Schlaich MP, Oehmer S, Schmieder RE. Hypercholesterolemia and treatments with statins do not alter L-arginine induced changes of renal hemodynamics. Nephrol Dial Transplant 2002; im Druck
19. Freed TA, Hager H, Vinik M. Effects of intra-arterial acetylcholine on renal arteriography in normal humans. Am J Roentenol Radium Ther Nucl Med 1968; 104:312-318
20. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288:373-376
21. Goonasekera CD, Rees DD, Woolard P et al. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 1997; 15:901-909
22. Herlitz H, Jungersten LU, Wikstrand J, Widgren BR. Effect of L-arginine infusion in normotensive subjects with and without a family history of hypertension. Kidney Int 1999; 56:1838-1845
23. Higashi Y, Chayama K. Renal endothelial dysfunction and hypertension. J Diabetes Complications 2002; 16:103-107
24. Higashi Y, Oshima T, Ozono R et al. Effects of L-arginine infusion on renal hemodynamics in patients with mild essential hypertension. Hypertension 1995; 25:898-902
25. Higashi Y, Oshima T, Sasaki S et al. Angiotensin-converting enzyme inhibition, but not calcium antagonism, improves a response of the renal vasculature to L-arginine in patients with essential hypertension. Hypertension 1998; 32:16-24
26. Jacobi J, Schneider MP, John S, Schmieder RE. Impact of NO-synthase inhibition on renal hemodynamics in normotensive and hypertensive subjects. J Hypertens 2002; 20:525-530
27. John S, Jacobi J, Delles C, Schaich MP, Schneider MP, Schmieder RE. Rapid improvement of nitric oxide bioavailability after lipid lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol 2001; 37:1351-1358
28. Kawagishi T, Matsuyoshi M, Emoto M et al. Impaired endothelium-dependent vascular responses of retinal and intrarenal arteries in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 1999; 19:2509-2516
29. Komers R, Komersova K, Kazdova L, Rizickova J, Pelikanova T. Effect of ACE inhibition and angiotensin AT1 receptor blockade on renal and blood pressure response to L-arginine in humans. J Hypertens 2000; 18:51-59
30. La Villa G, Barletta G, Pantaleo P et al. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. Hepatology 2001; 34:19-27
31. Mayer BX, Mensik C, Krishnaswami S et al. Pharmacokinetic-pharmacodynamic profile of systemic nitric oxide-synthase inhibition with L-NMMA in humans. Br J Clin Pharmacol 1999; 47:539-44
32. Mimran A, Ribstein J, DuCailar G. Contrasting effect of antihypertensive treatment on the renal response to L-arginine. Hypertension 1995; 26:937-941
33. Montanari A, Tateo E, Fasoli E et al. Angiotensin II blockade does not prevent renal effects of L-NAME in sodium-repleted humans. Hypertension 1997; 30:557-562
34. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333:664-666
35. Panza JA, Casino PR, Badar DM, Quyyumi AA. Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation 1993; 87:1475-1481
36. Perinotto P, Biggi A, Carra N et al. Angiotensin II and prostaglandin interactions on systemic and renal effects of L-NAME in humans. J Am Soc Nephrol 2001; 12:1706-1712
37. Raij L, Baylis C. Glomerular actions of nitric oxide. Kidney Int 1995; 48:20-31
38. Schlaich MP, Jacobi J, John S, Delles C, Fleischmann I, Schmieder RE. Is L-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature? Clin Sci (Colch) 2000; 99:293-302
39. Schmidt BMW, Delles C, Klingbeil AU, Schneider MP, John S, Schmieder RE. Is basal nitric oxide bioavailability similarly impaired in the forearm and the renal vasculature? (Abstrakt) Dtsch Med Wochenschr 2001; 126:S185(Suppl 3
40. Schmieder RE, Delles C, Müller HJ, Schneider MP, John S, Schulze B. Analysis of endothelial function in the human renal vasculature (Abstrakt). J Hypertens 2002:20 (Suppl 4); S109
41. Schmieder RE, Gatzka C, Schobel H et al. Renal hemodynamic response to stress is influenced by ACE-inhibitors. Clin Nephrol 1994; 42:381-388
42. Schmieder RE, Veelken R, Schobel HP et al. Glomerular hyperfiltration during sympathetic nervous system activation in early essential hypertension. J Am Soc Nephrol 1997; 8:893-900
43. Schneider MP, Klingbeil AU, Schmidt BMW, Fleischmann E, Schmieder RE. Vitamin C augments the renal response to L-arginine in smokers (Abstrakt). J Am Soc Nephrol 2001; 12:517
44. Segarra G, Medina P, Vila JM et al. Inhibition of nitric oxide activity by arginine analogs in human renal arteries. Am J Hypertens 2001; 14:1142-1148
45. Spahr L, Martin PY, Giostra E et al. Acute effects of nitric oxide synthase inhibition on systemic, hepatic, and renal hemodynamics in patients with cirrhosis and ascites. J Investig Med 2002; 50:116-124
46. Tangphao O, Grossmann M, Chalon S et al. Pharmacokinetics of intravenous and oral L-arginine in normal volunteers. Br J Clin Pharmacol 1999; 47:261-266
47. Vallance P, Leone H, Calver A, Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339:572-575
48. Wierema TK, Houben AJ, Kroon AA et al. Nitric oxide dependence of renal blood flow in patients with renal artery stenosis. J Am Soc Nephrol 2001; 12:1836-1843
49. Wolzt M, Schmetterer L, Ferber W et al. Effect of nitric oxide synthase inhibition on renal hemodynamics in humans: reversal by L-arginine. Am J Physiol 1997; 272:F178-F182
50. Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 1993; 92:652-662